Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone on HDL apolipoprotein A-I (apoA-I) and apoA-I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Millar, John S., Ikewaki, Katsunori, Bloedon, LeAnne T., Wolfe, Megan L., Szapary, Philippe O., Rader, Daniel J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: The American Society for Biochemistry and Molecular Biology 2011
Schlagworte:
Patient-Oriented and Epidemiological Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2999935/
https://ncbi.nlm.nih.gov/pubmed/20971975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P008136
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge